The first adrenaline nasal spray to treat the most severe allergic reactions: quick, simple and needle-free. Already approved by the EMA, it will arrive in Italy in 2026.
Who lives with the constant fear of one anaphylactic shock he usually carries a with him at all times adrenaline auto-injectorbut finally there is also the possibility of using one nasal spray. Is called EURneffy and, after the one for depression, it is the new nebulizer that contains theepinephrinethat is, adrenaline, and from 2026 will be available in Italy for the emergency treatment ofanaphylaxis.
Already approved byEMA (European Medicines Agency) and the American FDA (Food and Drug Administration), represents a concrete alternative to traditional intramuscular injections of epinephrine, offering a more simple, quick And accessible.
Millions of people involved
In Italy they are registered approximately every year 10,000 cases of anaphylactic shockwith the number of deaths reaching 70 per year. In Europebeyond 150 million people suffer from allergies and a fifth of those with severe forms live in constant fear of incurring anaphylactic shock.
This is a medical emergency that can arise within minutes after exposure to a allergen contained in a food or a drug, or following a insect biteand requires immediate intervention with theadrenaline to avoid fatal consequences.
Because it is innovative
The absolute novelty of the nasal spray it’s theextreme simplicity of use. Unlike the traditional injectorswhich require an intramuscular injection, the new device simply inserts into the nostril.
No needles, but an intuitive spray like those used when you have a cold, easier to use even under stress.
However, it acts as quickly as injections: absorbed through the nasal mucosaquickly reaches the bloodstream symptoms of anaphylactic shock they begin to regress five minutes after application, disappearing in about a quarter of an hour.
It also boasts a long 30 month shelf lifemuch more than the classic 12 or 18 months of conventional autoinjectors. It means lower costs and less waste of expired drugs.
Limitations and precautions
There are some though limitations as first and foremost the body weight: the drug is suitable only for people weighing more than 30 kilogramswhich excludes i younger children for which the use of the traditional injector remains necessary.
Furthermore, an evaluation of the effects of the spray is still needed in categories of patients still little treated in clinical studies, such as elderly people and people with previous cardiac pathologies.
Precisely for this reason, the adrenaline spray administered via the nasal route is not intended to completely replace auto-injectors, but rather represents aadditional option to the needle.
For those who know the risk well severe allergiesthe spray translates to greater security And better quality of lifealso eliminating the anxiety or panic that arises during emergencies.
